Motif Bio, which is developing novel antibiotics effective against multi-drug resistant bacteria, filed on Wednesday with the SEC to raise up to $40 million in an initial public offering. The company is currently listed under the symbol MTFB on LSE's AIM Market and has a market cap of £52 million.
The New York, NY-based company was founded in 2003 and plans to list on the Nasdaq under the symbol MTFB. SunTrust Robinson Humphrey is the sole bookrunner on the deal. No pricing terms were disclosed.
